CN113454209A - 通用型双阴性t细胞的制备和治疗用途 - Google Patents

通用型双阴性t细胞的制备和治疗用途 Download PDF

Info

Publication number
CN113454209A
CN113454209A CN201980092455.1A CN201980092455A CN113454209A CN 113454209 A CN113454209 A CN 113454209A CN 201980092455 A CN201980092455 A CN 201980092455A CN 113454209 A CN113454209 A CN 113454209A
Authority
CN
China
Prior art keywords
dnt
population
dnts
cells
days
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980092455.1A
Other languages
English (en)
Chinese (zh)
Inventor
张丽
J·B·李
H·康
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University Health Network
Original Assignee
University Health Network
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Health Network filed Critical University Health Network
Publication of CN113454209A publication Critical patent/CN113454209A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/12—Chemical aspects of preservation
    • A01N1/122—Preservation or perfusion media
    • A01N1/125—Freeze protecting agents, e.g. cryoprotectants or osmolarity regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/50—Cellular immunotherapy characterised by the use of allogeneic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C12N2500/92—Medium free of human- or animal-derived components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Engineering & Computer Science (AREA)
  • Environmental Sciences (AREA)
  • Dentistry (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201980092455.1A 2018-12-19 2019-12-19 通用型双阴性t细胞的制备和治疗用途 Pending CN113454209A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862782005P 2018-12-19 2018-12-19
US62/782,005 2018-12-19
PCT/CA2019/051866 WO2020124248A1 (en) 2018-12-19 2019-12-19 Production and therapeutic use of off-the-shelf double negative t cells

Publications (1)

Publication Number Publication Date
CN113454209A true CN113454209A (zh) 2021-09-28

Family

ID=71099979

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980092455.1A Pending CN113454209A (zh) 2018-12-19 2019-12-19 通用型双阴性t细胞的制备和治疗用途

Country Status (6)

Country Link
US (2) US20220073877A1 (https=)
EP (1) EP3898950A4 (https=)
JP (1) JP2022515144A (https=)
CN (1) CN113454209A (https=)
CA (1) CA3123467A1 (https=)
WO (1) WO2020124248A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102394512B1 (ko) * 2021-05-03 2022-05-06 주식회사 지씨셀 동결 활성화 림프구 및 이의 제조 방법
EP4458378A4 (en) * 2021-12-30 2025-07-09 Chongqing Prec Biotech Co Ltd TECHNIQUE FOR PREPARING A UNIVERSAL CAR-T CELL, AND APPLICATION OF A UNIVERSAL CAR-T CELL
JP2025517437A (ja) * 2022-05-20 2025-06-05 武田薬品工業株式会社 操作された免疫細胞を産生する方法
CN117860782B (zh) * 2024-03-11 2024-05-28 中国康复科学所(中国残联残疾预防与控制研究中心) 双阴性t细胞在制备治疗脊髓损伤的药物中的用途

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020039576A1 (en) * 2000-08-21 2002-04-04 Li Zhang Method of modulating tumor immunity
CN101313061A (zh) * 2005-11-18 2008-11-26 大学健康网络 扩增双阴性t细胞的方法
CN104109653A (zh) * 2014-06-12 2014-10-22 浙江瑞顺生物技术有限公司 利用无动物血清培养体系大规模扩增人外周血dnt细胞的方法
CN105483083A (zh) * 2016-01-20 2016-04-13 首都医科大学附属北京友谊医院 双阴性t细胞的转化扩增方法
US20170071983A1 (en) * 2015-09-15 2017-03-16 University Health Network Combination therapy with double negative t-cells
CN106574244A (zh) * 2014-06-11 2017-04-19 保利比奥斯博特有限公司 用细胞因子组合物扩增淋巴细胞用于主动细胞免疫治疗
CN107073039A (zh) * 2014-08-15 2017-08-18 大学健康网络 用于癌症治疗的免疫疗法
US20180104278A1 (en) * 2015-05-11 2018-04-19 University Health Network Method for expansion of double negative regulatory t cells

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019145956A1 (en) * 2018-01-25 2019-08-01 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Methods for improved immunotherapy

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020039576A1 (en) * 2000-08-21 2002-04-04 Li Zhang Method of modulating tumor immunity
CN101313061A (zh) * 2005-11-18 2008-11-26 大学健康网络 扩增双阴性t细胞的方法
US20090098095A1 (en) * 2005-11-18 2009-04-16 Li Zhang Method of expanding double negative t cells
CN106574244A (zh) * 2014-06-11 2017-04-19 保利比奥斯博特有限公司 用细胞因子组合物扩增淋巴细胞用于主动细胞免疫治疗
CN104109653A (zh) * 2014-06-12 2014-10-22 浙江瑞顺生物技术有限公司 利用无动物血清培养体系大规模扩增人外周血dnt细胞的方法
CN107073039A (zh) * 2014-08-15 2017-08-18 大学健康网络 用于癌症治疗的免疫疗法
US20180104278A1 (en) * 2015-05-11 2018-04-19 University Health Network Method for expansion of double negative regulatory t cells
US20170071983A1 (en) * 2015-09-15 2017-03-16 University Health Network Combination therapy with double negative t-cells
CN105483083A (zh) * 2016-01-20 2016-04-13 首都医科大学附属北京友谊医院 双阴性t细胞的转化扩增方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BRANSON CHEN等: "Targeting chemotherapy-resistant leukemia by combining DNT cellular therapy with conventional chemotherapy", 《JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH》, vol. 37, no. 88, pages 1 - 11, XP055720371, DOI: 10.1186/s13046-018-0756-9 *

Also Published As

Publication number Publication date
US20220073877A1 (en) 2022-03-10
WO2020124248A1 (en) 2020-06-25
JP2022515144A (ja) 2022-02-17
US20250235482A1 (en) 2025-07-24
EP3898950A1 (en) 2021-10-27
EP3898950A4 (en) 2022-10-05
CA3123467A1 (en) 2020-06-25

Similar Documents

Publication Publication Date Title
Lee et al. Developing allogeneic double-negative T cells as a novel off-the-shelf adoptive cellular therapy for cancer
Bordignon et al. Cell therapy: achievements and perspectives
Lee et al. Haploidentical natural killer cells infused before allogeneic stem cell transplantation for myeloid malignancies: a phase I trial
Childs et al. Bringing natural killer cells to the clinic: ex vivo manipulation
Safinia et al. Promoting transplantation tolerance; adoptive regulatory T cell therapy
CN1981031B (zh) 调节性t细胞及它们在免疫治疗和抑制自身免疫反应中的应用
US20250235482A1 (en) Production and therapeutic use of off-the-shelf double negative t cells
CN104245923B (zh) 同种异型抗原‑反应性调节t细胞的增殖
KR20170067751A (ko) 저산소 및 정상산소 교대 조건에서 골수 침윤성 림프구의 활성화
JP7584437B2 (ja) 抗ｂｃｍａ ｃａｒ ｔ細胞の製造
JP2023505102A (ja) ナチュラルキラー細胞を製造する方法およびその組成物
Baron et al. Clinical manufacturing of regulatory T cell products for adoptive cell therapy and strategies to improve therapeutic efficacy
Davis et al. Interleukin-7 permits Th1/Tc1 maturation and promotes ex vivo expansion of cord blood T cells: a critical step toward adoptive immunotherapy after cord blood transplantation
Killig et al. Tracking in vivo dynamics of NK cells transferred in patients undergoing stem cell transplantation
Grupp et al. Adoptive cellular therapy
KR20250006881A (ko) 혈액암의 치료를 위한 동종 t 세포
Domogala et al. Natural killer cells differentiated in vitro from cord blood CD34+ cells are more advantageous for use as an immunotherapy than peripheral blood and cord blood natural killer cells
Rassek et al. New player in CAR-T manufacture field: comparison of umbilical cord to peripheral blood strategies
US20230011889A1 (en) Genetically engineered double negative t cells as an adoptive cellular therapy
Deng et al. Prospects and limitations of NK cell adoptive therapy in clinical applications
Peters et al. Immunotherapy with regulatory T cells in transplantation
JPWO2011021503A1 (ja) 一過性生着ｃｔｌを含む医薬品組成物
Hasmim et al. Expression of CD94 by ex vivo-differentiated NK cells correlates with the in vitro and in vivo acquisition of cytotoxic features
Temples Engineered Three-Dimensional Tumor Models to Investigate Natural Killer Cell Migration and Interactions with Cancer Cells
WO2023125772A1 (zh) 一种修饰的肿瘤浸润淋巴细胞及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20210928

RJ01 Rejection of invention patent application after publication